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Abstract 
 
Marbelus is an Unani Medicine of unique combination of Bael (Aegle marmelos) fruit and 
Connessi (Holarrhena antidysenterica) bark, which is highly effective in diarrhoea, dysentery 
(Amoebic & Bacillary dysentery), giardiasis and helminthiasis. However, toxicity study of the 
Marbelus syrup is still lacking. The present study is to investigate the acute toxicity of Marbelus 
Syrup extract on Sprague Dawley rats at a dose of 2000 mg/kg body weight (BW). Sighting 
study was conducted in a stepwise procedure using the fixed doses of 5, 50, 300 and 2000 mg/kg 
BW. No signs of toxicity and no deaths were observed. Based on the sighting study, we selected 
a dose of 2000 mg/kg BW and observed for 14 days. The study includes control and treatment 
group, each consisting of 5 female rats. The single oral dose of the Marbelus syrup did not 
produce mortality or significant changes in the body weight, food and water consumption. In the 
female rats there was significant (p=0.045) increase (16.40%) in total protein where albumin 
content was increased (1.56%) but not significantly (p=0.458) different from their corresponding 
control values. The decrease in urea content (0.80% decrease; p=0.691) & uric acid content was 
decreased by (12.54%; p=0.203) which was not statistically significant. The increase in both 
HDL cholesterol content (10.13% increase; p=0.46) & total cholesterol content (14.89% 
increase; p=0.23) was not statistically significant. It was observed that  about 13.44% increase in 
triglyceride content of treated female rats in comparison to their control female rats which was 
statistically significant(p=0.030). However, total proteins were significantly increased indicating 
dehydration. Apart from triglyceride, other biochemistry parameters demonstrated no significant 
changes as compared to the control.   
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CHAPTER 1 
 
INTRODUCTION 
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1.1 Dysentery 
 
Dysentery broadly refers to infectious gastrointestinal disorders characterized by inflammation of 
the intestines, chiefly the colon. The World Health Organization (WHO) defines dysentery as 
any episode of diarrhea in which blood is present in loose, watery stools. Dysentery is spread 
among humans through contaminated food and water. Once a person is infected, the infecting 
organism lives in the intestines and is excreted through the stool of the infected person. With 
some infections, animals can also be infected and spread the disease to humans. Common 
bacterial causes of dysentery in the United States include infections with the 
bacteria Shigella and some types of Escherichia coli (E coli). Other less common bacterial 
causes of bloody diarrhea include Salmonella and Campylobacter infections. Dysentery is 
associated with environmental conditions where poor sanitation is prevalent. For example, 
childcare institutions in developing countries have higher rates of Shigella infection. Amebic 
dysentery, caused by the parasite Entamoeba histolytica, is most commonly found in tropical 
areas with crowded living conditions and poor sanitation. [1][2][3]                  
The signs and symptoms of dysentery can last for five to seven days or even longer. The course 
of the illness varies among individuals, as do symptoms. Some people suffering with dysentery 
have mild symptoms, while others may have severe diarrhea with or without vomiting that can 
pose a risk of dehydration. Fortunately, dysentery can be treated with antibiotics and antiparasitic 
medications. Untreated dysentery can lead to severe dehydration. Severe dehydration and 
electrolyte imbalances can result in shock or coma and may be life-threatening.[3] 
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1.2 Symptoms of Dysentery 
 
Dysentery causes irritation and inflammation of the intestines that may result in a number of 
symptoms. The symptoms can vary in intensity among individuals. The most common symptoms 
of dysentery are related to disturbances of the digestive system and include: 
 Abdominal bloating 
 Abdominal pain 
 Bloody diarrhea (may also be watery or with mucus) 
 Cramping 
 Flatulence 
 Nausea with or without vomiting 
As the dysentery infection progresses, other symptoms, including symptoms of dehydration, may 
develop. Other possible symptoms include: 
 Decreased urine output 
 Dry skin and mucous membranes (such as dry mouth) 
 Feeling very thirsty 
 Fever and chills 
 Muscle cramps 
 Muscle weakness (loss of strength) 
 Weight loss  [3] 
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1.3 Causes of Dysentery  
 
The bacteria Shigella and E coli and the amoeba Entamoeba histolytica are the most common 
causes of dysentery. These organisms are present in the stool (feces) of infected people and 
animals. The Entamoeba histolytica may uneventfully reside in the colon, but if it attacks the 
colon wall, it can cause dysentery. People with weakened immune systems are also more likely 
to develop amebic dysentery. 
 
Most commonly, dysentery is caused by drinking water or eating food from sources 
contaminated with feces containing the pathogens. Swimming in contaminated water may also 
result in dysentery. For this reason, dysentery occurs most frequently in people traveling to 
developing countries and in children who touch infected human or animal feces without proper 
hand washing. 
 
Common causes of dysentery include: 
Several organisms are known to cause dysentery, most commonly: 
Campylobacter 
Certain types of E coli 
Entamoeba histolytica 
Salmonella 
Shigella  
[3] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4
   
 
1.4 Treatments 
 
1.4.1 Antibiotics : 
Antibiotic medications that are effective in the treatment of dysentery caused by bacterial 
organisms include: 
 Ceftriaxone  
 Ciprofloxacin  
 Trimethoprim-sulfamethoxazole 
The most common treatment for amebic dysentery caused by Entamoeba histolytica is 
metronidazole , an antiparasitic medication.[3] 
 
1.4.2 Unani Medicine in Dysentery 
Dysentery or bloody flux is a disorder of the digestive tract which is characterized by the 
inflammation of the large intestine and is accompanied by severe colic pain, formation of ulcers 
and passage of liquid or semi formed stools. Mucus and blood can also be present in the feces. 
Dysentery is caused by protozoa and bacilli and can be acute or chronic in nature. Acute 
dysentery is characterized by pain in the abdomen, diarrhea and loose motions. At times only 
yellowish white mucus and blood from ulcers is present in the feces. The evacuations are 
preceded by pain and tenesmus. The patient feels a constant desire to evacuate, although there 
may be nothing to expel except for mucus and blood. In dysentery all the digestive processes are 
disturbed and the secretions are either stopped or changed. The saliva becomes acidic and the 
gastric juice becomes alkaline. 
Many antibiotics are used in dysentery & diarrhea disease. Besides these medicinal plants play a 
significant role to control the dysentery & diarrhea. 
5
   
 
Table 1.1: Unani Medicine Plants used in dysentery in Bangladesh. [4], [5] 
 
 
 
 Botanical Name No. Family Local Name Uses in the Unani System of 
Medicine 
1. 
 
Abelmoschus esculentus (L.)  
Moench 
Malvaceae Dheros Fruits are boiled and taken to treat  
diarrhoea and dysentery.  
2. Abelmoschus moschatus  
Medik.  
 
Malvaceae Mushakdana The fruit is cooked and taken to treat  
dysentery 
3. 
 
Achyranthes aspera L Amaranthaceae Apang The leaf juice is taken to treat dysentery 
4. 
 
Aegle marmelos (L.) Corrêa Rutaceae  Bel The ripe fruit is taken to treat diarrhoea  
and dysentery.  
The leaves are eaten with chili and salt to 
treat diarrhoea and dysentery.  
5. 
 
Alpinia conchigera Griff. Zingiberaceae Konchi  
elachi  
The rhizome juice is taken to treat  
diarrhoea and dysentery.  
6. Amorphophallus  
paeoniifolius (Dennst.)  
Nicolson 
Araceae Ol Kachu The tuber is cooked and taken to treat  
diarrhoea.  
7. Anacardium occidentale L Anacardiaceae Kajubadam The decoction of the bark is taken to treat  
diarrhoea and dysentery 
8. Phyllanthus emblica L.  
 
Euphorbiaceae Amloki  Dried fruits are used to prepare medicine  
for diarrhoea and dysentery  
9. Zingiber officinale  
 
Roscoe 
Zingiberaceae  
Ada Root The root is chewed to treat 
dysentery.  
Juice extracted from the roots of the plant  
is taken for diarrhoea 
10. 
 
Ocimum americanum L.  Lamiaceae,   Ban Tulshi  Leaf Infusion of leaves is taken orally to 
treat 
11. 
 
Murraya koenigii (L.) 
Spreng.  
 
Rutaceae  
 
Chotokamini  
 
Leaf The leaves of the plant are used in  
diarrhoea and dysentery. 
12. Elaeocarpus floribundus  
Blume  
 
Elaeocarpaceae  
 
Jalpai  
 
 The fruit is taken to treat dysentery and  
diarrhoea. 
13. Daucus carota Dysentery,  
diarrhoea  
 
L. Apiaceae Gajor The extract of root is taken to treat  
dysentery.  
Decoction prepared from the root is taken  
for diarrhoea 
14. Dillenia indica L.  Dilleniaceae  Chalta  The fruits are taken to treat diarrhoea and  
dysentery.  
15. Momordica charantia L.  
 
Cucurbitaceae Korolla  
 
Leaf Infusion of leaves is taken to treat  
diarrhoea and dysentery. 
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1.5 Background of Unani Medicine in Bangladesh 
 
In Bangladesh traditional system of medicine namely Unani & Ayurvedic medicine have been 
used in medical practice for thousands of years & have played a significant role in maintaining 
human health. Most of the people of Bangladesh meet their health needs with traditional 
medicine as they are unable to access modern allopathic medicine due to poverty. 
Bangladesh National Formulary of Unani Medicine is compiled by the National Unani and 
Ayurvedic Formulary Committee and published by the Bangladesh Board of Unani and 
Ayurvedic Systems of Medicine, 38, Bangabandhu Avenue, Dhaka-1000 under the authority 
vested in the Board vide section13(J) of the Bangladesh Unani and Ayurbedic practitioners 
ordinance, 1983 in collaboration with the World Health Organization. Directorate of Drug 
Administration has issued Notification DA/Admin/1-10/96/6212 dated 19th October 1996 has 
issued license under Drug Act, 1940 and Rules there under and Drug(Control) Ordinance 1982 
for local manufacturer and sale in Bangladesh.(Published Bangladesh Gazette#24 Part VI dated 
Thursday, June 11th 1998.)  . Nowadays some western and developed countries are using 
traditional medicine for different health ailments to avoid the toxicity and side effects of 
synthetic and semi synthetic drugs. As traditional medicine is cheap, easily available and above 
all as because of natural origin, people can use this medicine with minimal health hazard and 
side effects. To strengthen the system of traditional medicine, the Government of Bangladesh has 
appointed thirty Unani and Ayurvedic Medical Officers in secondary levels hospitals under 
HPSP (Health and Population Sector program) from1999. They are providing health services 
with the existing health facilities without a uniform treatment guideline available to them so that 
the service could be rational and cost effective.  
The government of Bangladesh has also taken step to appoint traditional Graduate physicians to 
the remaining district hospitals and all the Upazila Health Complexes to expand this system. 467 
Herbal gardeners and 64 support personnel have already been recruited to assist the traditional 
medical officers and to take care the newly created 467 herbal gardeners in the district and 
Upazila Health Complex premises. They will also influence the people to use traditional 
medicine with the qualified herbal physicians and help to make the service easy and available for 
7
   
 
the rural and urban people. To maintain the quality, safety and efficacy of herbal medicine the 
preparation of pharmacopoeia for traditional medicine is under process under HNPSP program. 
All the above activities have become possible due to the commitment of the Government and the 
support of World Health Organization.[6] 
1.6 Statement of Purpose 
In the absence of an efficient primary health care system, traditional medicine occupies a central 
place in the provision of health care, especially among rural communities of developing 
countries. The strong historical bond between plants and human health is well substantiated by 
plant species’ diversity and related knowledge of their use as herbal medicines. [7] In addition, it 
is attributable to the accessibility and affordability of herbal medicines. [8]  
Since time immemorial, man has made use of plants in the treatment of diseases. The 
pharmacopoeias of many countries of the world include even today a large number of drugs of 
plant origin. While it is true that purely synthetic compounds are being employed in increasing 
measure, in clinical practice, interest in the examinations of plants as potential source of new 
drug has never waned.  
 The task of revival of the old system of medicine however, is not an easy one at the present 
time. Advances in knowledge are so vast and occurs so fast in every time that an investigator is 
overwhelmed by the application of a new material with which he is confronted. There comes a 
time, however, when we feel like going back to the ancient page and leave where secrets remain 
to be revealed and unfold. We are fortunately endowed with a very rich flora, because of the size 
of our country and varieties of climatic and soil conditions, obtained in the different parts and as 
such there is wonderful opportunity for working on plant products. [9]  
 
Another fortunate factor is that herbal medicines do not produce many side effects commonly 
seen after long-term administration of synthetic drugs, resulting in a revival of interest in their 
use all over the world in both developing and developed countries. [10] In a recent survey it has 
been seen that 25-30% prescriptions, even in some developed countries contain plant ingredients. 
With the fast growing demand for herbal drugs in the last two decades in every branch of 
medical care, it was considered expedient if not imperative to explore the therapeutic claims with 
8
   
 
least side effects of reported herbal drugs in reference monograph to serve the clinicians and 
scientists alike of both modern and herbal system of medicine. [11] 
 
Now a day’s most of the individuals are preferring to take herbal medicine to control their health, 
not only in prevention of diseases but also to treat them because natural remedies are somehow 
safer and more efficacious than remedies that are pharmaceutically derived.[10] Hamdard 
Laboratories (Waqf) Bangladesh has been manufacturing and practicing Unani medicines  since 
long time. These of unani medicines are widely prescribed for the treatment of various illnesses 
because many people cannot afford the use of expensive modern medicine. 
One of such medicine is Marbelus syrup. It is an Unani Medicine of unique combination of 
Bael (Aegle marmelos) fruit and Connessi (Holarrhena antidysenterica) bark, which is highly 
effective in diarrhoea, dysentery (Amoebic & Bacillary dysentery), giardiasis and helminthiasis. 
The bioactive compounds of Aegle marmelos are effective in diarrhoea, dysentery and peptic 
ulcer. Marbelus syrup relieves dysentery, bacillary dysentery, piles and diarrhoea. It relieves 
acute stomachache and duodenal inflammation. The bioactive compound of Holarrheana 
antidysenterica destroys amoeba. Now it has become imperative to conduct research on herbs to 
find out the toxicity and effectiveness of drugs for the benefit of man and animals and discard the 
ineffective, toxic and worthless drugs. 
Therefore, the present study was conducted to determine the toxicity of the drug Marbelus 
Syrup being manufactured and marketed by Hamdard Laboratories (Waqf) Bangladesh and to 
validate the claim that Unani medicines are safe. With this perspective the present study has 
planned to evaluate the toxicity by using rats.  
The research work has been designed based upon the effect of Marbelus Syrup on the level of 
 Total Serum Protein & Albumin 
 Lipid profile 
 Liver Function 
 Kidney function  
 Serum Uric Acid 
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2.1 Review of Literature 
 
This chapter provides an overview of (1) toxicity and the various definitions of key toxicity 
terms used in this report, (2) the current use and importance of herbal medicines, their traditional 
dosage forms and mode of administration of herbal medicines as well as some specific aspects of 
their toxicity, viz. possible causes, prevalence and the evaluation of herbal toxicity, 
 
2.1.1 Definition of Toxicity 
Toxicity is defined as “the potential of a substance to exert a harmful effect on humans or 
animals, and a description of the effect and the conditions or concentration under which the 
effect takes place”. [12] 
In order to support an application for a clinical trial or for the registration of a new drug, it is 
necessary to satisfy legislation that requires that certain data should be produced from a variety 
of toxicological investigations that show the safety profile of the compound to which humans 
may be exposed.  Therefore, in the majority of cases of evaluation of the toxicity of most 
substances, rodents and non-human primates are first used in preclinical animal safety studies 
before further studies are done in humans.  These animals are mainly used because of their 
biological similarity to humans that allows them to be regarded as the suitable metabolic models 
for humans in a broad range of investigations. [13], [14] 
 
In general, toxicity testing methods can be divided into two categories: The first category 
comprises tests that are designed to evaluate the overall effects of compounds on experimental 
animals. Individual tests in this category differ from each other basically in regard to the duration 
of the test and the extent to which the animals are evaluated for general toxicity. These tests are 
classified as acute, prolonged and chronic toxicity tests. [13] The second category of tests consists 
of those that are designed to evaluate specific types of toxicity in detail. The prolonged and 
chronic tests do not detect all forms of toxicity, but they may reveal some of the specific 
toxicities and indicate the need for more detailed studies. Thus, this second category of tests has 
been developed for the determination of effects of compounds on the fetus in a pregnant animal 
11
   
 
(teratogenic tests), on the reproductive capacity of the animals (reproduction tests), on the 
genetic system (mutagenic tests), for the determination of the ability of agents to produce tumors 
(tumorigenicity and carcinogenicity tests), etc. [13], [15] 
 
In this report, the focus was on the first category of toxicity testing methods, viz. acute toxicity 
tests.  The primary concern was to determine how toxic the Unani Medicine might be after acute 
administration to rat.  
2.1.2 Acute Toxicity 
Acute toxicity has been defined as “the ability of a substance to cause severe biological harm or 
death soon after a single exposure or dose; or any poisonous effect resulting from a single short-
term exposure to a toxic substance”. [16]An acute toxicity test is a single test that is conducted in a 
suitable animal species and may be done for essentially all chemicals that are of any biologic 
interest. Its purpose is to determine the symptomatology consequent to administration of the 
compound and to determine the order of lethality of the compound.  The test consists of 
administering the compound to the animals on one occasion. [13], [14], [15] 
Furthermore, acute toxicity tests are those designed to determine the effects, which occur within 
a short period after dosing. They serve to establish the lethal dose range of the test substance and 
provide prompt warning if a highly toxic compound is being dealt with. [17]  
They also provide information on the limiting toxicity arising from the pharmacological effects 
of the compound on target organs and, often, on the maximum dose to be used in subsequent 
sub-acute studies (chronic studies). This latter information is particularly important for predicting 
the amount of chemical required for future toxicological studies. [17]  
The initial procedure, in an acute toxicity test programme, is to test a series of rangefinding 
single doses of the compound in a single animal species. This necessitates selection of a route of 
administration, preparation of the compound in a form suitable for administration via the selected 
route and selection of an appropriate experimental animal species. [17] Generally, even if the 
intended use of the compound does not involve the oral or parenteral routes, at least the oral 
route is used, in addition to other routes, so that comparison with other related compounds can be 
made. Additionally, such testing may also indicate the viability of the oral route for use in 
12
   
 
subsequent, more extensive and prolonged toxicity studies.[13] Normally, the significance and use 
of the data that are obtained are limited to those routes of administration that were used in the 
actual experiment.   
As usual, all initial acute toxicity tests are performed on either rats or mice because of the low 
cost, the availability of the animals, and the fact that abundant reference toxicological data for 
many compounds in these species are available. [13] In addition, these animals generally 
metabolize compounds in a similar manner to humans and the compounds (including 
metabolites) may have similar pharmacodynamics in the animals and humans.  Before the 
experiment is performed, a total number of animals of similar body weight and same sex, or 
equal numbers of both sexes, are selected and randomly assigned to test (treatment) and control 
groups. After exposure to single doses of the test compound (or treatment), the animals are 
monitored for a minimum of 24hrs for any clearly recognized effect (such as changes in 
locomotor activity; bizarre reactions; sensitivity to pain, sound and touch; changes in social 
interaction; aggressive behavior; convulsions; paralysis, etc.) seen, as an index of toxicity, 
shortly or/and consistently after the administration of the chemical.[13],[15]  However, the most 
easily recognized and certainly the most significant of effects is that of death and this outcome is 
usually used as a primary measure of acute toxicity.  If the animals appear to be healthy at the 
end of 24hrs, they are monitored at daily intervals for at least a further one to two weeks for the 
appearance of delayed toxicity. [13], [14], [15] 
 
In the rodents, three types of acute toxicity studies may be performed. For the first type of study, 
it is usual to establish the maximum tolerated dose (i.e. the highest dose after which the animals 
recover completely from all effects of the chemical) and the minimum lethal dose for the 
compound (or treatment). The second type of study is the single dose study to establish the target 
organ(s) for toxicity while the third type of study is for the determination of the precise LD50 or 
median lethal dose. The results of the latter type of study may be required, in most countries, for 
a clinical trial’s certificate or even for a product licence.[14],[15],[17] Usually, to establish a LD50, at 
least four dose levels are used, with 5-10 male animals plus 5-10 females per treatment group. 
The animals are given a single dose of test compound and, at the end of 14-days observation 
period, the major organs and abnormal tissues of the surviving animals are collected and 
subjected to histopathological investigation.  
13
   
 
The LD50 and its confidence limits are calculated from the lethality data using probit analysis.[14]  
Since a great range of concentrations or doses of various chemicals may be involved in the 
production of harmful effects, the LD50 has been used by some authors to devise categories of 
toxicity on the basis of the amounts of the chemicals necessary to produce harm. An example of 
such a categorization, along with the respective lethal doses, is given in the following Table.   
 
Table 2.1 Classification of toxicity based on LD50 dose ranges. [13], [14]  
 
Category LD50 (mg/kg) LD50 (mg/kg) Classification 
Extremely toxic  1 or less < 5 Super- toxic 
Highly toxic 1 to 50 5- 50 Extremely toxic 
Moderately toxic 50 to 500 50- 500 Very toxic 
Slightly toxic 500 to 5000 500- 5000 Moderately toxic 
Practically non-toxic 5000 to 15000 5000- 15000 Slightly toxic 
Relatively harmless More than 15000  
 
> 15000  
 
Practically non-toxic 
 
   
 
2.1.3 Chronic Toxicity 
Chronic toxicity is defined as “the capacity of a substance to cause poisonous health effects in 
humans, animals, fish and other organisms after multiple exposures occurring over an extended 
period of time or over a significant fraction of an animal’s or human’s lifetime ”. The purpose of 
the chronic toxicity test is to investigate the harmful effects that foreign compounds that are 
introduced to animals in repeated doses or in continuous exposure over an extended period of 
time may produce.[17]  The dose levels of compounds used usually range from a very low fraction 
of the therapeutically effective dose (i.e. somewhere in the range of the ED 50 for the compound 
in that species, or of the same order as the anticipated human therapeutic dose range) to doses 
that approach the maximum non-lethal dose (as established in rodent acute toxicity studies) [17], 
[13]. 
 Different approaches to dose ranging studies are applied depending on the species being used. 
The procedures used can vary, but usually involve exposing the experimental animals (in typical 
group sizes of two to five animals/sex/group) to various doses of the test compound, i.e. from the 
maximal non-lethal dose (determined in the acute studies) down to doses in the pharmacological 
dose range. Clinical chemistry and haematological parameters are then measured at the start of 
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the study (i.e. within 48 hours after the first dose) and at the end of the study, along with full 
histopathology analysis of all abnormal tissues plus the major organs (such as the heart, liver, 
kidneys, lungs and brain of the animals), at least at the end of the study. [17], [15]   
 
2.1.4 Toxic effects 
 Toxic effects are defined as “harmful responses of a biological system to a toxic compound, and 
death of cells or the whole organism are the major response.” [15]   
In all the cases, the toxic effects are usually manifested either in an acute or a chronic manner, 
and occur mostly as a result of an acute or chronic exposure to toxic compound by oral ingestion, 
inhalation or absorption following skin contact.[15] The toxic effects are seen as (1) signs or 
reflection of a disturbance of the normal activities of enzymes that perform essential biochemical 
roles in all forms of life; (2) alteration of the normal activities of plasma membrane that regulate 
the exchange of nutrients and metabolites between the cell and its surroundings and (3) the 
disturbances of other normal cell activities, e.g. RNA and DNA synthesis, growth, division and 
general metabolism at all levels of organization from sub-cellular to organ and organ 
system.[14],[15]  
  The way in which the toxic agent is introduced into the body also plays a significant role. 
Routes of administration   
 
This term refers to the way in which drugs or compounds are introduced to animals or humans. 
To evaluate toxicity of a compound in animals various routes may be used, but two most 
commonly used modes of administration for animals studies are via intraperitoneal injection or 
the oral route. [17]   
 
Intra-peritoneal injection  
 
 This is one of the methods of dosing, which may occasionally provide information about local 
as well as systemic toxicity. To give drugs by intraperitoneal dosing, the animal is laid on its 
back and the abdomen shaved. This area is thoroughly cleansed and, using an appropriate syringe 
and needle, the abdominal wall is punctured. To ensure minimal danger of perforation of 
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abdominal viscera, the injection should be made rostral and lateral to the bladder at an angle of 
about 15º to the abdomen. The depth of penetration should not exceed 5mm. [17], [18] 
  
Oral administration  
 
 The oral route is probably one of the most common means by which a chemical enters the body.  
In short, the oral administration is the form of administration involving the gastrointestinal tract, 
which may be viewed as a tube going through the body, starting at the mouth and ending at the 
anus. Although it is within the body, its contents are essentially exterior to the body fluids. Most 
orally administered chemicals can otherwise have a systemic effect on the organism only after 
absorption has occurred from the mouth or the gastrointestinal tract. Oral administration of 
chemicals that are rapidly absorbed from the gastrointestinal tract would theoretically expose the 
liver to concentrations of the agent that would not be obtained if other routes of administration 
were used.[13] Furthermore, if a compound entered the enterohepatic cycle, at least a portion of 
the compound would be localized in the organs involved in the cycle. Compounds that are 
known to be toxic to the liver would be expected to be more toxic following oral administration 
on repeated occasions, whereas their administration by other routes may be less hazardous.[13],[18] 
   
2.2.1 Current use and importance of herbal medicines 
A World Health Organisation survey indicated that about 70-80% of the world’s populations rely 
on non-conventional medicine mainly of herbal sources in their primary healthcare. This is 
especially the case in developing countries where the cost of consulting a western style doctor 
and the price of medication are beyond the means of most people. [19], [20] Bangladesh possesses a 
rich flora of medicinal plants. Out of the estimated 5000 species of different plants growing in 
this country more than a thousand are regarded as having medicinal properties. Use of these 
plants for therapeutic purposes has been in practice in this country since time immemorial. 
Continuous use of these plants as items of traditional medicine in the treatment and management 
of various health problems generation after generation has made traditional medicine an integral 
part of the culture of the people of this country. As a result, even at this age of highly advanced 
allopathic medicine, a large majority (75-80%) of the population of this country still prefer using 
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traditional medicine in the treatment of most of their diseases even though modern medical 
facilities may be available in the neighborhood. [5] Use of herbal medicines is thus, widespread in 
the world and in Bangladesh, but still very little is known about these medicinal plants.  
A medicinal plant is factually any plant which in one or more of its parts contains substances that 
can be used for therapeutic purposes or which are precursors for the synthesis of direct 
therapeutic agents. [21] On the other hand, the knowledge and practice of herbal medicine, is 
assumed to be an acquisition of hundreds years of trial and observation handed down from 
generation to generation verbally or in writing. Specifically, in African traditional medicine, a 
treatment usually consists of a complex mixture of several extracts or the active principles of 
plants and often only one of the ingredients is responsible for the claimed therapeutic 
activity.[21],[22],[23] 
Plants were once a primary source of all the medicines in the world and they still continue to 
provide mankind with remedies. Examples include “Quinine” obtained from Cinchona spp and 
used against malaria (antiprotozoal); “Taxol” from Taxus brevifolius,used as anticancer and 
“Atropine” from Datura spp, used as mydriatic and antispasmodic. Today, still about one–
quarter of all marketed orthodox pharmaceutical medicines is either derived from plant sources 
or from derivatives of secondary plant metabolites .[24],[19] However, presently the rate for the 
successful discovery of new drugs from natural sources is not very promising. Several factors are 
responsible for this state of affairs of which the major factor is the triumph of synthetic-
chemistry by which natural extracts have, in the pharmaceutical industry, been replaced with 
synthetic molecules that often has no connection to natural products. Nevertheless, various 
chemicals and biotechnological products of plant origin are being screened by major 
multinational pharmaceutical industries in the hope of finding new cures for diseases that are 
better than current therapies in terms of effectiveness, selectivity and reduced side effects. [19],[25] 
Other factors that sustain the low rate of success of herbal medicines as a potential source of new 
drugs are, firstly, the challenge and difficulty of acquiring well-documented plant material and 
the non-scientific process by which folk therapy systems operate, i.e. herbal medicine is often 
accused of being more based on faith.[23] Secondly, and perhaps one of the greatest arguments 
against herbal medicine today, is the lack of scientific proof of its efficacy. Thirdly, witchcraft 
and the evil aspects associated with herbal medicine also discredit this form of medicine. Finally, 
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further shortcomings of herbal medicine are the imprecise diagnosis that is often made by 
practitioners of this type of medicine and the absence of precise dosages for many herbal 
treatments. [21] In recent years, however, it has been noted that plants are arguably poised for a 
comeback as sources of human health products. The hope for this comeback is rooted in the 
unique and newly appreciated properties of phytochemicals vis-à-vis conventional new 
chemicalentities-based pharmaceuticals, and are based on (1) the enormous propensity of plants 
to synthesize mixtures of structurally diverse bioactive compounds with multiple and mutually 
potentiating therapeutic effects; (2) the low-cost and highly scalable protein and secondary 
metabolite biomanufacturing capacity of plants; (3) the perception that because of the history of 
human use and co-evolution of plants and humans, phytochemicals provide a safer and more 
holistic approach to disease treatment and prevention.[25]Although the above properties of plants 
have been known for a long time, the ability to better exploit the uniqueness of plant therapeutics 
was only recently acquired as a result of the dramatic advances in metabolic engineering, 
biochemical genomics, chemical separation, molecular characterization and pharmaceutical 
screening. A challenge for phytochemical-based botanical therapeutics is to integrate the ability 
to identify and genetically manipulate complex biosynthetic pathways in plants with better 
characterization of genetic targets for the prevention and treatment of complex diseases. [25], [19] 
Notwithstanding the above, to date, the medicinal plant preparations are, in most cases, still used 
in their traditional dosage forms with ingredients that are poorly defined.  
 
2.2.2 Traditional dosage forms and mode of administration 
           of herbal medicines 
 
When considering the traditional dosage forms of herbal medicine, several additional factors are 
also noteworthy. Firstly, the most common methods for administering traditional medicines are 
orally, sublingually, rectally, topically, nasally, smoking, steaming and bathing.[24] Secondly, the 
method of preparation of the traditional dosage form is most of the time also critical, since it 
deals with the amount of fresh or dry plant material to be used, the addition of appropriate 
volumes of solvents such as water or alcohol and additional activities such as boiling for a 
specified length of time or partial burning to achieve a desired color.[24] The additional activities 
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are usually intended to neutralize certain toxins or to increase the extraction of the active 
compound in the aqueous form of medicines. The method of administration and the method of 
preparation of the herbal dosage form can be expected to have a significant impact on the 
effectiveness of the various traditional dosage forms of herbal medicine used. The following are 
examples of preparations commonly employed for therapeutic purposes via various specific 
routes of administration: (1) enemas, which are aqueous or oily solutions or suspensions, 
intended for rectal injection.; (2) the decoction, the extract of any plant drug obtained by boiling, 
as well as the infusion which is an extract prepared by macerating the crude drug for a short 
period of time in cold or boiling water, both intended for administration by mouth; (3) snuffs, 
preparations of finely powdered, dried medicinal plants that can be drawn up into the nostrils 
through inhalation;(4) inhalants, powder for licking, under the skin  implantations, bath mixtures, 
poultices, balms, internal cleansing solutions and lotions are intended either for bathing with, 
rubbing into incisions, anointing, inhaling as smoke, licking or applying to skin or nibbling 
on.[24],[21] Among other dosage forms not normally traditionally used but also very convenient are 
herbal tablets and capsules. Despite being quite useful, tablets may, however, contain fixed 
formulations that may not readily be adaptable to the individual’s specific needs.  Capsules 
appear to be a more convenient form to take powdered plant drugs because they mask the 
unpleasant tastes or textures of the powdered forms of plant drugs and this is a distinct advantage 
for delivery of plant ingredients into the gastrointestinal tract.[23] Given the variety of traditional 
dosage forms, methods of preparation and modes of administration used with herbal medicine, as 
well as the general non-professionalism many of the traditional medicinal practitioners display 
with respect to these activities and the impact that these processes may have on the effective use 
of herbal products, much concern has recently emerged over aspects of the efficacy, safety and 
quality of treatment methods and products obtained from herbal or natural sources. Particularly, 
there is a concern that many herbal practitioners continue to use plants (and dosage forms and 
routes of administration) for the treatment of diseases without any knowledge of the toxicity 
profiles or safety of their plant materials. [19], [23] 
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2.2.3 Toxicity aspects of use of herbal preparations 
 
Currently, there is an ongoing world-wide “green” revolution which is mainly premised on the 
belief that herbal remedies are safer and less damaging to the human body than synthetic 
drugs.[26] Many writers claim that it is assumed that “all things natural are good”[27] and, 
generally, the extensive traditional use of herbal products is not assumed to be based on a 
comprehensive well documented logic, but rather on empirical wisdom accumulated over many 
years, often arrived at through trial and error and transmitted orally from generation to 
generation. This traditional methodology has enabled those herbal medicines producing acute 
and obvious signs of toxicity to be well recognized and their use avoided. However, the premise 
that “traditional use of a plant for perhaps many hundreds of years establishes its safety does not 
necessarily hold true”. [28]The more sdubtle and chronic forms of toxicity, such as 
carcinogenicity, mutagenicity, and hepatotoxicity, may well have been overlooked by previous 
generations and it is these types of toxicity that are of most concern when assessing the safety of 
herbal remedies. [26], [22] Safety should be the overriding criterion in the selection of medicinal 
plants for use in health care systems. [22] As with all forms of self-treatment, the use of herbal 
medicinal products also presents a potential risk to human health. As far as medicinal plants go, 
there are a few main categories of safety concerns.  Firstly, there is the extrinsic or non-plant 
associated category where the patient may be at risk of toxicity as a result of exposure to (1) 
accidental or deliberate contaminants present in the herbal product or to (2) substitutes of herbal 
material. Secondly, we have the intrinsic or plant associated category of safety concerns. In this 
category, the patient may be exposed to potentially toxic substances naturally present in the 
herbal products or materials. Thirdly, there is the category of safety concerns related to 
interactions when the use of synthetic prescription drugs is combined with herbal medicines. 
 Finally, another category of safety concerns arises where specific patient groups may be at risk, 
e.g. pregnant or nursing mothers, children and the elderly. [22], [28]   
There can thus be several causes of toxicity with herbal products. 
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2.2.3.1. Causes of toxicity with herbal products 
 
All chemicals may be considered toxic under certain conditions, e.g. even pure water when 
inhaled is rapidly absorbed across the lung alveoli to cause lysis of red blood cells. But some 
chemicals present a greater hazard than others.[14] A large number of plants contain appreciable 
levels of biosynthetically produced chemical substances and many of these have either been 
reported to be toxic to humans or are predictably toxic based on extensive animal or in vitro 
studies. [22] 
Toxicity with medicinal plant products may arise in various ways, but in general two categories 
of causes can be distinguished:  In the first category, as previously mentioned, the toxicity may 
be as a result of exposure to intrinsic ingredients of some medicinal plants. Examples of some 
more important classes of ingredients implicated here include: pyrrolizidine alkaloids, which are 
said to be hepatocarcinogens; aristolochic acid I, said to bemutagenic and carcinogenic; phorbol 
esters, which are tumor promoters and vesicant to the skin; carboxyactractyloside, a deadly toxic 
compound; amygdalin, a cyanogenic compound with many undesired effects; etc.[27],[22]  
 In addition, several studies conducted on flavonoids indicate that, besides their apparently 
beneficial health effects, they may also induce  utagenicity and genotoxicity (e.g. quercetin) in 
both bacterial and mammalian experimental systems.[29] The second category of causes of 
toxicity of herbal medicines is more extrinsic or non-associated with the plant active 
constituents. In this category, the toxicity is a result of exposure to plant products contaminated 
with excessive or banned pesticides, microbial contaminants, heavy metals or chemical toxins, or 
with substituted ingredients. The pesticide, heavy metal and microbial contaminants may be 
linked to the source, collection or processing of the herbal materials (e.g. in contaminated 
environments). Chemical toxins may arise due to incorrect storage conditions or chemical 
treatment during storage.[19] [27],[22] Some of these environmental factors can be controlled by 
implementing standard operating procedures that lead to good agricultural, good laboratory, 
good supply and good manufacturing practices for producing medicinal products from herbal or 
natural sources .[19]  
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2.2.3.2 Prevalence of toxicity with herbal products 
 
Different retrospective studies done over the last 20 years indicated that the incidence of deaths 
occurring due to exposure to plants (as a proportion of total patients poisoned by traditional plant 
medicine) was about 1.5% in France, 5% in Belgium, 6.5% in Italy, 7.2% in Switzerland and 6% 
in Turkey.[27] The total number of deaths due to exposure to plants throughout the world 
however, is very difficult to establish and must certainly be underestimated since all cases of 
such deaths were, from analytical and forensic points of view, not always well documented and 
thus, rarely published. Nevertheless, it seems that death due to plant poisoning might be more 
important than other causes of poisonings. For instance, in South Africa, 2% of the people 
admitted for acute poisoning died compared to 15% of the patients poisoned with traditional 
plant medicine.[27] From published reports, it appears that side effects or toxic reactions, of any 
form but associated with herbal medicines, are rare.[22] This may be because herbal medicines are 
generally safe, that adverse reactions following their use are underreported, or because the side 
effects are of such a nature that they are not reported. [22], [27] 
There is, therefore, a need for the public to have an understanding of the risks posed by herbal 
medicines so as to ensure that such products are used safely. Particularly, as highlighted above, 
the safety of some herbal products is compromised by lack of suitable control of the quality of 
herbal medicines and the absence of appropriate herbal use information for patients. To 
appropriately inform and protect the public, the herbal products must, however, first be evaluated 
for its toxicity. 
2.2.3.3. Evaluation of herbal toxicity 
 
Herbal toxicity can be evaluated by (1) observing human or animal populations exposed to the 
plant material, (2) administering the plant medicine to animals under controlled 20 conditions 
and observing the effects (in vivo) and (3) exposing cells, sub-cellular fractions or single-celled 
organisms to the plant material (in vitro). [15] In this report the focus is more on the in vivo model. 
Ethically, toxicity of a compound cannot randomly be evaluated in humans. Nevertheless, the 
exposure of humans to toxicity with herbal materials, as highlighted previously on point 2.2.3.1, 
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may occur accidentally when these are part of their therapeutic activities or intentionally as with 
drugs and food additives.[19] In such cases, the accidents resulting from this type of exposure 
may, if well monitored and recorded (i.e. by measuring substances and their metabolites in body 
fluids and using biological indices of pathological change), provide important information about 
the toxicity of a plant material in humans. However, acquiring such data is often difficult and 
rarely complete, and the latter is the main reason why procedures for animal toxicity testing have 
been maintained as a successful alternative for evaluating the harmfulness of compounds for 
humans. [15], [22]  As previously reported in sections 2.1.2 and 2.1.3, to date, the majority of data 
on the toxicity of chemicals, including drugs and herbal medicines, is gained from experimental 
studies done in animals (in vivo). The data so acquired are used for the risk assessment and 
safety evaluation of drugs (or herbal medicines) prior to human exposure. Because animal tests 
can be carefully controlled with the exact known doses being used, the quality of the data 
obtained is generally reliable. [15] The number of animals used should be enough to allow 
statistical significance to be demonstrated and the application of humane conditions and proper 
treatment of the animals are essential, for scientific as well as ethical reasons, to help ensure that 
the data are reliable and robust. [15][19] In a toxicity study, the animal species selected will depend 
partly on the type of toxicity test, existing data available and also on ethical and financial 
considerations. The most common species used are rats and mice for reasons of size, 
accumulated knowledge on 21 these species and cost, besides the similarity of their metabolism 
to that of humans. [15], [13] In the present study, the concern was on the evaluation of the toxicity 
of Marbelus Syrup after the administration of the syrup (contains bioactive compounds-Aegle 
marmelos & Holarrheana antidysenterica) to rats. As part of the effort of quality assurance of 
herbal products, scientific experiments were to be carried out to assess the safety of this 
medicinal plant using the rat as an alternative mammalian species. 
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3.1 Study Location 
This study was carried out at laboratory of Brac University, Dhaka, Bangladesh & biochemical 
analysis has been done at Armed Forces Institute of Pathology, Dhaka Cantonment, Dhaka, 
Bangladesh.    
3.2 Drug 
Marbelus was used in the present study that was obtained from Hamdard laboratories (Waqf) 
Bangladesh in liquid dosage form. The Human Dose of Marbelus is 2-4 teaspoon per day. 
3.3 Animals 
For this toxicological research work, healthy Albino rats (Rattus novergicus: Sprague-Dawley 
strain,) of eight weeks old were obtained from Animal House of the Department of Pharmacy, 
Jahangirnagar University. These animals were apparently healthy and weighed 50-70 g.  
3.4 Animal Care 
The experimental animals were housed individually in plastic cages having dimensions of         
30 X 20 X13 and soft wood shavings were employed as bedding in cages for the duration of the 
study.  Animals were maintained in the laboratory of  Brac University,Dhaka, Bangladesh under 
standard conditions (temperature 25 [+ or -] 2 [degrees]C, relative humidity 75 [+ or -] 5% and 
12-h light and dark cycle). Feeding of animals was done at libitum, along with drinking water 
and maintained at natural day night cycle. Constant environmental parameters with adequate 
nutritional conditions were maintained. The rats were fed with “mouse chow” (prepared 
according to the formula developed at BCSIR, Dhaka). All experiments on rats were carried out 
in absolute compliance with the ethical guide for care and use of laboratory animals. The 
experiment animals were marked carefully on the tail which helped to identify a particular 
animal. By using identification mark response were noted separately for a particular rat prior to 
and after the administration. The experimental animals were acclimatized for 5 to 7 days before 
commencement of the study. 
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3.5 Study design & selection of doses 
Acute oral toxicity test was carried out according to the Organization for Economic Co-operation 
and Development (OECD) guidelines for Testing of Chemicals number 420. [30] The study was 
initiated with a sighting study aimed to determine the dose for the acute toxicity study. The 
sighting study comprised of female Sprague Dawley (SD) rats dosed in a stepwise procedure 
using the fixed doses of 5, 50, 300 and 2000 mg/kg. Starting with 5 mg/kg Body Weight (BW), 
the test article was administered orally to one rat. The rat was then observed for toxic effect for 
the first 30 min followed by hourly for 8 h for the first 24 h. If there are no signs of toxic effect 
or mortality observed on the rat within the 24 hours, then it was dosed another rat with the next 
dose (50 mg/kg BW) and a similar procedure was carried out. A stepwise procedure was carried 
out until the highest dose, 2000 mg/kg BW is reached. If all the rats survived, they were 
monitored and observed once daily for the next 13 days. The sighting study showed that the rats 
dosed with 5, 50 300 and 2000 mg/kg BW with the test article survived. Based on this 
observation it was decided to use the highest dose, 2000 mg/kg BW for the main test, the acute 
toxicity study. The acute toxicity study comprised of two groups, one control and one treatment 
group that consisted of 5 female rats in each group. Female rats were chosen because it is the 
most sensitive gender to see the effect of treatment.[30],[31] The treatment group received 
Marbelus Syrup  at a dose 2000 mg/kg BW given orally once, in a 2 ml volume. The control 
group received water delivered in the same volume and same procedure as the treatment group. 
The experimental animals were observed for 30 min after treatment, followed by observation 
hourly for 8 h and once daily for the next 13 days. 
3.6 Physical observation and mortality  
Clinical observation were made once a day for mortality, moribund, ill health or reaction to 
treatment, such as changes in skin and fur, eyes and mucus membranes, behavior pattern, 
tremors, salivation, diarrhea, sleep and coma. 
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3.7 Body weight, food and water consumption   
The body weights (BW) of each rat were recorded once weekly. The differences of the BW were 
recorded. The amounts of test article to be given were calculated again weekly based on the new 
BW of the experimental rats to ensure a constant dose volume per kg BW of the test article given 
to the rats. The amounts of food place in the food tray were about 200 g and this amount was 
enough for a week. However, the amount of food left in the tray at the end of the week was 
calculated to obtain the amount of food consumed. The amounts of water placed in the bottle 
were 200 ml. The level of the water was measured weekly. The amounts of water consumed 
were calculated from this information.   
3.8 Biochemical Analysis   
On the necropsy day, blood was withdrawn through cardiac puncture (Or whenever possible) 
from the posterior vena cava by dissecting the animals under chloroform anesthesia. The blood 
samples approximately (3 to 6 ml) were withdrawn and transferred into heparinised tubes 
immediately. Clinical biochemistry values were measured by coordination with ARMED 
FORCES INSTITUTE OF PATHOLOGY, DHAKA CANTONMENT,DHAKA, 
BANGLADESH.   Biochemical values determinations were for liver profile (Total protein & 
albumin), Renal profile (urea & uric acid), lipid profile (HDL-Cholesterol, Cholesterol & 
triglyceride). Total Protein Content of the samples was assayed by the Biuret method . [32] Serum 
albumin concentration was determined using the method of Bromocresol Green (BCG) 
method.[33] Triglycerides concentration was determined by   Glycerol-3-Phosphate Oxidase 
(GPO) & Phenol-aminophenazone (PAP) method. Serum total cholesterol & high density 
lipoprotein cholesterol were determined by Cholesterol Oxidase (CHOD) & Phenol-
aminophenazone (PAP) method.[34] The serum urea concentration was determined by the method 
of Kaplan.[35] Uric Acid concentration was determined by Phenol-aminophenazone (PAP) 
method.[34] The absorbances of all the tests were determined using spectrophotometer. 
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3.9 Test procedure for Total Protein   
Reagent: Total Protein Liquicolor 
Origin:  Human GmbH, Germany 
Method: Biuret Method. 
Requirements: 
A)  SPECTROPHOTOMETER 
B) Micropipettes, 5-50 µl, 100-1000 µl and 20-200 µl 
C) Tips, 1-200 µl, 200-1000 µl 
D) Total Protein Reagents 
REAGENT PREPARATION: 
                    The reagent & standard are ready for use. 
REAGENT STABILITY: 
                      Up to expiry date at 2ºC to25ºC 
SPECIMEN:  
                   Serum, Plasma 
Filter: 546nm 
Reaction Type: End Point 
Working Procedure: (only one blank is required for a series of tests). 
 Blank Standard Tests 
Total Protein Reagents 1000µl 1000µl 1000µl 
Protein Standard -   20µl - 
Serum/Plasma -   -  20µl 
                                                                       Mix Well 
                                                                                              
 
                                                 Incubate at 20ºC to 25ºC for 10 min. 
                                                                 
                                             Read with Spectrophotometer against Reagent Blank. 
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3.10 Test procedure for Albumin   
 
Reagent: Albumin Liquicolor 
Origin:  Human GmbH, Germany 
Method: BCG (Bromocresol Green) 
 
Requirements: 
A)  SPECTROPHOTOMETER 
B) Micropipettes, 5-50 µl, 100-1000 µl and 20-200 µl 
C) Tips, 1-200 µl, 200-1000 µl 
D) Albumin Reagents. 
 
REAGENT PREPARATION: 
                    The reagent & standard are ready for use. 
 
REAGENT STABILITY: 
                      Up to expiry date at 2ºC to25ºC 
SPECIMEN:  
                   Serum, Plasma 
Filter: 546nm 
Reaction Type: End Point 
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Working Procedure: (only one blank is required for a series of tests). 
 
 Blank Standard Tests 
Albumin  Reagents 1000µl 1000µl 1000µl 
Albumin  Standard -   10µl - 
Serum/Plasma -   -  10µl 
                                                                       Mix Well 
                                                                                        
 
                                                Incubate at 20ºC to 25ºC for 10 min. 
                                                                         
                                                     Read with Spectrophotometer against Reagent Blank.                                                 
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3.11 Test procedure for Triglycerides 
Reagent: Triglycerides Liquicolor 
Origin:  Human GmbH, Germany 
Method: GPO-PAP 
Requirements: 
A)  SPECTROPHOTOMETER 
B) Micropipettes, 5-50 µl, 100 – 1000 µl, 20 – 200 µl 
C) Tips, 1- 200 µl, 200- 1000 µl 
D) Triglycerides Reagents. 
 
REAGENT PREPARATION: 
                    Reagent-2 and standard are ready for use. 
 
REAGENT STABILITY: 
 
Up to expiry date when store at 2ºC to 8ºC. 
 
SPECIMEN: 
 
Serum, Plasma 
 
Reaction Type: End Point. 
 
Filter: 546 nm. 
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Working Procedure: (Only one blank is required for a series of tests). 
 Blank Standard Tests 
    
TG Reagents 1000 µl 1000 µl 1000 µl 
TG Standard - 10 µl - 
Serum/Plasma - - 10 µl 
 Mix Well 
  
 Incubate at 37ºC for 5 min 
 or 
 At Room Temp for 10 – 15 min 
  
 Read with SPECTROPHOTOMETER against Reagent Blank. 
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3.12 Test procedure for Cholesterol   
Reagent: Cholesterol Liquicolor 
Origin:  Human GmbH, Germany 
Method: CHOD-PAP 
Requirements: 
A)  SPECTROPHOTOMETER 
B) Micropipettes, 5-50 µl, 100 – 1000 µl, 20 – 200 µl 
C) Tips, 1- 200 µl, 200- 1000 µl 
D) Cholesterol Reagents. 
 
REAGENT PREPARATION: 
                    The reagent and standard are ready for use 
 
REAGENT STABILITY: 
 
Up to expiry date when store at 2ºC to 8ºC. 
 
SPECIMEN: 
 
Serum, Plasma 
 
Reaction Type: End Point. 
 
Filter: 546 nm. 
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Working Procedure: (Only one blank is required for a series of tests). 
 Blank Standard Tests 
    
Cholesterol Reagents 1000 µl 1000 µl 1000 µl 
Cholesterol Standard - 10 µl - 
Serum/Plasma - - 10 µl 
 Mix Well 
  
 Incubate at 37ºC for 5 min 
 Or 
 At Room Temp for 10 – 15 min 
  
 Read with SPECTROPHOTOMETER against Reagent Blank 
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3.13 Test procedure for HDL-Cholesterol 
Reagent: Precipitant and Standard, Total Cholesterol Reagents 
Origin:  Human GmbH, Germany 
Method: CHOD-PAP 
Requirements: 
 
A)  SPECTROPHOTOMETER 
B) Micropipettes, 5-50 µl, 100 – 1000 µl, 20 – 200 µl 
C) Tips, 1- 200 µl, 200- 1000 µl 
D) HDL (Precipitant Reagents), Cholesterol Reagents. 
REAGENT PREPARATION: 
 
                    The reagent and standard are ready for use in case Macro Method, in case of Semi 
micro method Precipitate reagents (PREC) diluted 4 part PREC with 1 part Distilled Water. 
 
REAGENT STABILITY: 
Up to expiry date when store at 2ºC to 8ºC. 
 
SPECIMEN: 
Serum, Plasma 
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Working Procedure in two step: 
Step 1: 
Precipitation Step. 
Precipitate Reagent (PREC) 
SI Macro Semi Micro 
Precipitation Reagent 1000 µl 500 µl Diluted PREC 
Serum 500 µl 200 µl 
 
Mix and Incubate 10 min at room temperature. 
 
Centrifuge 10 min at 4000 g 
After Centrifugation 
 
 
 
 
 
 
                                                                                                   Supernatent 
  
                                                                                                    Pellet 
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Step- 2: 
Reagent: Total Cholesterol  
Reaction Type: End Point 
Filter: 546 nm. 
Working Procedure: (Only one blank is required for a series of tests). 
 Blank Standard Tests 
    
Total Cholesterol 
Reagents 
1000 µl 1000 µl 1000 µl 
HDL Cholesterol 
Standard 
- 100 µl - 
Supernatant (Step- 1) - - 100 µl 
 Mix Well 
  
 Incubate at 37ºC for 5 min 
 Or 
 At Room Temp for 10 – 15 min 
  
 Read with SPECTROPHOTOMETER against Reagent Blank. 
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3.14 Test procedure for Urea 
Reagent: Urea Liquicolor 
Origin:  Human GmbH, Germany 
 
Requirements: 
A)  SPECTROPHOTOMETER 
B) Micropipettes( To be pipetting 10µl & 1 ml) 
C) Tips 
D) Urea Reagent 
 
REAGENT PREPARATION: 
                    Reagent-2 and standard are ready for use 
 
Enzyme Reagent 1a: 
                      Enzyme Concentrate 1 ml+100 ml Reagent-1  
But, for one test Enzyme concentrate 10 µl + 1 ml Reagent-1,  
    1ml=1000 µl 
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Working Procedure: 
 
 Blank Standard Test 
    
Enzyme Reagent-1a 
(Above Proportionate to 
Enzyme + Reagent-1) 
1000 µl 1000 µl 1000 µl 
Standard - 10 µl - 
Sample - - 10 µl 
 Mix and incubate for 5 min at Room temperature or 3 min at 37ᴼC 
Reagent 2 1000 µl 
(1 ml)  
1000 µl 
(1 ml) 
1000 µl 
(1 ml) 
 Mix and incubate for 5 min at Room temperature or 3 min at 37ᴼC 
 
 
Filter: 578 nm 
Reaction Type: End Point 
Zeroing-Reagent Blank 
Normal Range: 10-50 mg/dl 
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3.15 Test procedure for Uric Acid   
Reagent: Uric Acid Liquicolor 
Origin:  Human GmbH, Germany 
Method:  PAP Method 
Requirements: 
A)  SPECTROPHOTOMETER 
B) Micropipettes 5-50µl, 100-1000 µl and 20-200 µl 
C) Tips 1-200 µl, 200-1000 µl 
D) Uric Acid  Reagents 
REAGENT PREPARATION: 
                    The reagent & standard are ready for use. 
REAGENT STABILITY: 
                      Up to expiry date when store at 2ᴼC to 8ᴼC. 
SPECIMEN:  
                   Serum, Plasma. 
Filter: 546nm 
Reaction Type: End Point 
Working Procedure: (only one blank is required for a series of tests). 
 Blank Standard Tests 
Albumin  Reagents 1000µl 1000µl 1000µl 
Albumin  Standard -   10µl - 
Serum/Plasma -   -  10µl 
                                                       Mix Well 
                                                                                        
 
                                      Incubate at 20ºc to 25ºc for 10 min. 
                                                                         
                                 Read with Spectrophotometer against reagent blank. 
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3.16 Statistical analysis 
 
All findings such as body weight changes, food and water consumption and blood chemistry 
were tabulated and analyzed. Statistical analysis involved use of the Statistical Package Sciences 
(SPSS) (14.0 Version). Data are expressed as the mean ± standard deviation. The mean value (x) 
and standard deviation (SD) were calculated for each variable measured and were analyzed 
statistically by analysis of variance (ANOVA) to determine significant differences between 
groups at p<0.05. The analysis and comparison were evaluated for significant at 5% (a = 0.05). 
[36]. 
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CHAPTER 4 
 
RESULTS  
                                    &                     
                               DISCUSSIONS 
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4.1 Sighting study 
 
The sighting study did not result with any signs of toxic effect at all, the dose level tested, 5, 50, 
300 and 2000 mg/kg BW. All the rats survived. Based on this observation we then selected a 
dose level of 2000 mg/kg BW for the main test (Acute Toxicity Study). 
 
4.2 Physical observation and mortality 
 
The acute toxicity study did not result in any mortality of treatment rats and no toxic effects were 
observed throughout the 14 days study period. Physical observation of the test article-treated rats 
throughout the study indicated that none of the them showed signs of toxic effect such as 
changes on skin and fur, eyes and mucus membrane, behavior pattern, tremors, salivation, 
diarrhea, sleep and coma. No mortality was observed in any of the rats. 
 
4.3 Body weight, food and water consumption 
 
 
The body weight of the sample rats treated with Marbelus Syrup and control rats were as shown 
in Table 4.1. There were gradual increases in body weight of treatment and control rats. The 
body weight of the treatment rats were not significant different as compared to the control rats. 
The percentage increase in body weight of treatment rats measured weekly on Day 7 and 14 were 
found 11.24 and 11.00%, respectively. The food and water consumption of the treatment rats 
were also not significantly different as compared to the control rats measured throughout the 
study (Table 4.1). 
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Table 4.1 Body weight (g), food consumption (g) and water intake (ml) by control and rats 
treated with Unani medicine (Marbelus Syrup) 
         Body Weight(g) Food Consumption(g) Water Intake(ml) 
 Week 1 Week 2 Week 1 Week 2 Week 1 Week 2 
Control 59.50±7.93 64.50±8.85 45.86±3.13 52.33±2.58 145.00±21.02 148.83±5.49 
Experiment 
(2000 
mg/kg) 
65.75±5.61 72.98±5.62 49.14±4.22 48.66±8.47  151.66±7.53 152.20±4.92 
 
 
4.4 Clinical biochemistry 
 
The clinical biochemistry values of total protein and triglycerides were elevated in the treatment 
rats as compared to the control rats, with significant value at p=0.045 and p=0.030 respectively 
(Table 4.2). Other clinical biochemistry parameters measured, albumin, urea, uric acid, HDL-
cholesterol & cholesterol of the treatment rats were not significantly different as compared to the 
control.   
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Table 4.2: Clinical biochemistry values of control & rats treated with Marbelus Syrup  
(2000mg/kg) during the acute toxicity study.  
The Clinical biochemistry data was measured by spectrophotometer. 
 
Blood/Serum biochemistry 
measured  
Control Rat Treated Rat 
Liver Profile   
Total Protein 79.25±3.82 g/l 92.25±2.02 g/l 
Albumin 16.00±0.41g/l 16.25±0.63 g/l 
 
Renal profile 
  
Urea 9.99±0.41mmol/l 9.91±0.37 mmol/l 
Uric acid 255.78±64.52 µmol/l  223.06±23.98 µmol/l 
   
 
Lipid Profile 
  
HDL-Cholesterol                                2.27±0.09 mmol/l 2.50±0.06 mmol/l 
Cholesterol 2.35±0.099 mmol/l 2.7±0.0456 mmol/l 
Triglycerides 1.19±0.18 mmol/l 1.35±0.05 mmol/l 
Values are expressed as mean ± standard deviation, n = 5. *p < 0.05 significant value. 
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4.5 Total Protein Content 
       Fig-4.1: Effect of Marbelus syrup on Serum total protein level in rats. 
 
Parameters Control VS sample 
Total Protein Control±SEM 
79.25±3.82 g/l 
Sample±SEM 
92.25±2.02 g/l 
                                                        Note: *p<0.05 
Results: 
Total serum protein concentration in sample group (92.25±2.02 g/l) was significant (p=0.045) 
increase than control (79.25± 3.82 g/l).  
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4.6 Albumin Content 
 
 
Fig-4.2: Effect of Marbelus syrup on Serum Albumin level in rats 
Parameters Control VS Sample 
Serum Albumin Control±SEM 
16.00±0.41g/l 
Sample±SEM 
16.25±0.63g/l 
                                                        Note: *p<0.05 
Results: 
Serum Albumin concentration in sample group (16.25±0.63g/l) was not statistically significant 
(p=0.458) than control (16.00± 0.41 g/l).  
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4.7 Urea Content 
 
 
Fig-4.3: Effect of Marbelus Syrup on Urea level in rats 
 
Parameters Control VS Sample 
Urea Control±SEM 
9.99±0.41mmol/l 
Sample±SEM 
9.91±0.37 mmol/l 
                                              Note: *p<0.05 
Results: 
Urea concentration in Sample group (9.91±0.41mmol/l) was not statistically significant 
(p=0.691) than control (9.99± 0.41 mmol/l).  
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4.8 Uric Acid Content 
 
Fig-4.4: Effect of Marbelus Syrup on Uric Acid level in rats 
 
Parameters Control VS Sample 
Uric Acid Control±SEM 
255.78±64.52µmol/l 
Sample±SEM 
223.06±23.98 µmol/l 
                                           Note: *p<0.05 
 
Results: 
Uric Acid concentration in sample group (223.06±23.98 µmol/l) was decreased than control 
(255.78± 64.52 µmol/l) but not statistically significant (p=0.203). 
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4.9 HDL- Cholesterol Content 
 
 
Fig-4.5: Effect of Marbelus Syrup on HDL- Cholesterol level in rats 
 
Parameters Control VS Sample 
HDL- Chlesterol Control±SEM 
2.27±0.09 mmol/l 
Sample±SEM 
2.50±0.06 mmol/l 
                                          Note: *p<0.05 
Results: 
HDL- Cholesterol concentration in Sample group (2.50±0.06 mmol/l ) was not statistically 
significant(p=0.46)  than control (2.27±0.09 mmol/l).  
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4.10 Cholesterol Content 
 
 
Fig-4.6: Effect of Marbelus syrup on Cholesterol level in rats 
 
Parameters Control VS Sample 
Cholesterol Control±SEM 
2.35±0.099 mmol/l 
Sample±SEM 
2.7±0.0456 mmol/l 
                                          Note: *p<0.05  
Results: 
Cholesterol concentration in Sample group (2.7±0.0456 mmol/l) was not statistically significant 
(p=0.23)   than control (2.35±0.099 mmol/l).  
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4.11 Triglycerides Content 
 
Fig-4.7: Effect of Marbelus syrup on Triglycerides level in rats 
 
Parameters Control VS Sample 
Triglycerides  Control±SEM 
1.19±0.18 mmol/l 
Sample±SEM 
1.35±0.05 mmol/l 
                                           Note: *p<0.05 
Results: 
Triglycerides concentration in Sample group (1.35±0.05 mmol/l) was statistically significant 
(p=0.030)   than control (1.19±0.18 mmol/l).  
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4.12 Discussion 
Herbal medicine, a natural remedy has become universally popular in primary healthcare, 
particularly in developing counties. Herbal sources are presumed to be safe without any 
compromising health effect, thus widely used as self medication. [37] The use of   herbal   
preparations   as   a   treatment   of diseases is very common. In Bangladesh, rural communities 
used herbs as food and traditional medicine. Marbelus syrup containing Aegle marmelos & 
Holarrhena antidysenterica has been used traditionally by some population as sarbat, dysentery 
& diarrhea. Some of these usages have been studied in in vitro and in animal model. Total 
alcoholic, total aqueous, whole aqueous and methanolic extracts were collected from the leaves 
of A. marmelos [38] and studied in experimental rats for their toxicity. No histopathological 
changes were found when extracts of A. marmelos were administered intraperitoneally   for 14 
days successively at the dose of 50 mg/kg body wt. The collected data demonstrate that the 
extracts of the leaves of A. marmelos have a high margin of drug safety. Since the Aegle 
marmelose extract has previously been shown to be pharmacologically active (hypoglycemic) 
when orally administered to rats [39], [40],[ 41] at the minimum active dose of mg/kg body wt, one 
may conclude that the active compounds present in the Aegle marmelose extract exhibit a rather 
low acute oral toxicity profile. The extract of Holarrhena antidysenterica has no toxic effect in 
research by the monitoring of GOT (Serum aspartate glutamate transferase) and GPT (Serum 
alanine glutamate transferase) activities in liver and kidney. [42] Scientific evidence for their 
efficacy is widely studied but systemic safety studies are lacking.  Therefore it is essential to 
evaluate the toxicity of the Marbelus syrup animals to ensure of its safety. The Marbelus syrup 
did not affect the body weight of the treated rats when compared to the control rats. Food and 
water intake of the treated rat and control group were similar. The increase in body weight of 
both group weekly were about 11 g, which considered normal and gradually as observed in SD 
rats of similar age group. The single oral dose of the Marbelus syrup did not produce mortality or 
significant changes in the body weight, food and water consumption. In the female rats there was 
significant (p=0.045) increase (16.40%) in total protein where albumin content was increased 
(1.56%) but not significantly (p=0.458) different from their corresponding control values. The 
decrease in urea content (0.80% decrease; p=0.691) & uric acid content was decreased by 
12.54%; p=0.203 which was not statistically significant. The increase in both HDL cholesterol 
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content (10.13% increase; p=0.46) & total cholesterol content (14.89% increase; p=0.23) was not 
statistically significant. It was observed that  about 13.44% increase in triglyceride content of 
treated female rats in comparison to their control female rats which was statistically 
significant(p=0.030). Liver profiles were not significantly different as compared to the control 
except for total protein value. Triglycerides level in the treatment rats was significant different as 
compared to the control rats. Renal profile such as urea, uric acid  were all normal as control 
group and indicated that there were no renal damage caused by Marbelus syrup to the rats.  
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                 Conclusion 
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Conclusion 
 It was concluded that the acute toxicity study of Marbelus syrup at 2000 mg/kg BW 
administered orally to Sprague Dawley rats did not caused any death or acute adverse effect on 
the clinical observation and mortality to the treatment rats. However, from the blood 
investigation, it showed that Marbelus Syrup consumption may cause dehydration as 
demonstrated by increased in total protein level. Other parameters except triglyceride were 
normal. No-observed-adverse-effect-level (NOAEL) of the Marbelus syrup is considered to be 
up to 2000 mg kg-1 day-1 for 14 days in rats. Thus, the lethal oral dose of Marbelus syrup is 
classified under category five, which is not at or below 2000 mg kg-1. This study provides 
valuable data on the toxicity profile of Marbelus syrup of Aegle marmelos & Holarrhena 
antidysenterica that would be useful in further pharmacological studies. 
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